What Wegovy Does to Your Body, Step by Step

Wegovy contains semaglutide, a GLP-1 receptor agonist that acts on appetite-regulating centres in the brain as well as on the gut.
It slows gastric emptying, meaning food stays in your stomach longer and fullness signals last further into the day.
In the STEP 1 clinical trial (68 weeks, adults with obesity), participants lost an average of around 15% of body weight on the 2.4mg maintenance dose.
Wegovy is licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition — suitability is always decided by a prescriber.

Wegovy (semaglutide 2.4mg) works by mimicking a gut hormone your body already makes, slowing digestion, reducing hunger signals in the brain, and helping you feel full on less food. Those changes happen in a specific sequence — and understanding that sequence explains both the results people see and the side effects they sometimes feel along the way. Wegovy is a prescription-only medicine; a clinician assesses whether it is right for you before any treatment begins.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

How semaglutide reshapes hunger, digestion and weight, what the evidence shows

Step 1: semaglutide finds its target in your gut and brain

The first thing Wegovy does after each weekly injection is bind to GLP-1 receptors. GLP-1 (glucagon-like peptide-1) is a hormone your intestine releases naturally after eating; it tells your brain the meal is done and signals the gut to slow down. Semaglutide is a synthetic version of that hormone, modified so it stays active in your body for about seven days rather than a few minutes.

Within hours of the injection, two things happen in parallel. In the gut, the rate at which your stomach empties into the small intestine drops, food lingers, so the physical sensation of fullness extends well beyond the meal itself. In the brain, semaglutide acts on the hypothalamus, the region that governs appetite and energy balance. The reward value of food (the pull you feel towards high-calorie options) tends to diminish. Many people describe this as food simply becoming less interesting, rather than feeling they are resisting it.

This dual action on gut and brain is why the mechanism feels different from older approaches. If you want to understand what semaglutide does to the body at a deeper level, you can also read a more detailed breakdown of how Wegovy works inside your body if you want to go further into the physiology.

Step 2: your body adjusts over the titration period

Wegovy treatment starts at 0.25mg and increases gradually over roughly 16 weeks toward the 2.4mg maintenance dose. That escalation exists for a reason. The same mechanisms that reduce appetite also slow gastric motility, and if the dose rises too quickly the GI system can react sharply, nausea, loose stools, and reflux are the most common complaints, and they are most noticeable in the first week or two after each increase.

Going slowly lets the body recalibrate. Most people find that by the time they reach a higher dose, the side effects from the previous level have settled. The titration schedule is set by your prescriber, not something to adjust yourself; the full semaglutide guide covers the schedule in more detail.

One practical point worth knowing: because gastric emptying slows, oral medicines taken at the same time may be absorbed differently. This is particularly relevant for oral contraceptives; NHS guidance recommends discussing contraception with your prescriber before starting.

Step 3: the changes you notice over weeks and months

The effects people actually feel (eating smaller portions without trying, stopping mid-meal, thinking about food less) build gradually over the titration period and tend to be most pronounced at the maintenance dose. If you are curious about what exactly Wegovy does to your body across all these systems, we cover the full picture in a dedicated guide. The mechanism does work differently from willpower; it changes the biology driving appetite rather than relying on you to override it.

In the STEP 1 trial, published in the New England Journal of Medicine, adults taking semaglutide 2.4mg alongside lifestyle support lost around 15% of body weight on average over 68 weeks. That figure matters because it came from a controlled setting, real-world results vary by starting weight, diet, activity and adherence.

NICE recommends semaglutide (Wegovy) within specialist weight management services for adults meeting specific BMI criteria, for a maximum of two years. The question of what Wegovy does to your stomach specifically (including the gastric-emptying changes) is covered separately if that is what prompted your search.

What to watch for, and when to get medical help

Common side effects are mostly GI-led: nausea, constipation, diarrhoea, indigestion, and fatigue are all reported, particularly in the early weeks. For most people they are mild to moderate and ease with time. Serious reactions are rare but need prompt attention.

Seek urgent medical help if you develop severe, persistent abdominal pain that radiates to your back, with or without vomiting, this can be a sign of pancreatitis, which the MHRA's Yellow Card scheme lists as an infrequent but serious known effect of GLP-1 medicines. Other reasons to contact a clinician promptly: signs of an allergic reaction, gallbladder symptoms (pain in the upper right abdomen), or significant dehydration from persistent vomiting or diarrhoea.

Wegovy is not recommended during pregnancy, breastfeeding, or for anyone actively trying to conceive. It is not licensed for under-18s. Anyone with a history of certain thyroid or pancreatic conditions will need to discuss this with a prescriber before starting.

If you are also wondering whether supplements might interact with your treatment, our guide to apple cider vinegar and Wegovy is worth a read before combining the two. And if you are weighing this up against other options, the weight-loss treatment overview sets out what is available through a UK-licensed private route.

Wegovy is a prescription-only medicine. Every consultation at nume is reviewed personally by a GPhC-registered Independent Prescriber before anything is dispensed. If you are ready to find out whether it might be right for you, start your free consultation and a clinician will review your answers the same day.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions